Physician profile
Jihua Cheng
NPI 1902098544
$497.24
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $165 · 2020: $17.36 · 2021: $191 · 2022: $124.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Servier Pharmaceuticals LLC | $159.26 | 2021 | |
| Puma Biotechnology, INC. | $106.11 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $45.59 | 2019-2022 | |
| Abbvie INC. | $37.93 | 2019-2022 | |
| Genzyme Corporation | $31.26 | 2022 | |
| Incyte Corporation | $28.64 | 2022 | |
| Amgen INC. | $19.56 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.45 | 2019 | |
| Coherus Oncology, INC. | $17.36 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $16.63 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $15.45 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jihua Cheng listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.